JOINT VENTURE PARTNERSHIPS AND EQUITY METHOD INVESTMENTS

At December 31, 2018, the Company had investments in the following unconsolidated joint venture partnerships and equity method investments:



Locations	Net Investment		Interest Owned
Joint Venture Partnerships:
Alberta, Canada (2)	$	40.9	43.37	%
Florence, South Carolina	10.1		49.00	%
Equity Method Investments:
Various	9.5		various

The joint venture partnerships are governed by agreements that mandate unanimous agreement between partners on all major business decisions as well as providing other participating rights to each partner. The equity method investments represent the Company’s purchase of ownership interests in clinical diagnostic companies. The investments are accounted for under the equity method of accounting as the Company does not have control of these investments. The Company has no material obligations or guarantees to, or in support of, these unconsolidated investments and their operations.

Condensed unconsolidated financial information for joint venture partnerships and equity method investments is shown in the following table.



As of December 31:	2018		2017
Current assets	$	67.9	$	45.7
Other assets	15.7		14.4
Total assets	$	83.6	$	60.1
Current liabilities	$	33.3	$	31.6
Other liabilities	5.8		1.0
Total liabilities	39.1		32.6
Partners' equity	44.5		27.5
Total liabilities and partners’ equity	$	83.6	$	60.1



For the period January 1 - December 31:	2018		2017		2016
Net revenues	$	186.3	$	212.5	$	156.7
Gross profit	62.4		62.6		45.7
Net earnings	34.4		25.7		20.3

The Company’s recorded investment in one of its Alberta joint venture partnerships at December 31, 2018, includes $32.3 of value assigned to that partnership’s Canadian license to conduct diagnostic testing services in the province. Substantially all of the joint venture's revenue is received as reimbursement from the Alberta government's healthcare programs (AHS). While the Canadian license provides the joint venture the ability to conduct diagnostic testing in Alberta, it does not guarantee that the provincial government will continue to reimburse diagnostic laboratory testing in future years at current levels. A decision by the provincial government to limit or reduce its reimbursement of laboratory diagnostic services would have a negative impact on the profits and cash flows the Company derives from the joint venture. In August 2016, AHS and the Canadian partnership reached an agreement to extend the contract for five additional years through March 2022, with the intent to have the services provided pursuant to the contract transferred to AHS at the end of the five-year period. In consideration of AHS acquiring the assets and assuming liabilities in accordance with the parties’ agreement, AHS will pay CAD 50.0 to the partnership when the transfer is effective, subject to a working capital adjustment. The Company is amortizing the value of the partnership's Canadian license to its residual value over the remaining term of the agreement.

As a result of the acquisition of PAML, the Company acquired PAML’s ownership interests in six joint ventures. During 2017 and 2018, the Company further acquired the ownership interests of the other members of four of the six joint ventures, and divested interest in one of the six joint ventures to the other member. The Company and the other members of the sixth joint venture made the decision to dissolve the sixth joint venture to be effective in 2019.